Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients

Pediatric Transplantation
Bilio PaouriEugenios Goussetis

Abstract

Pediatric HSCT recipients are at high risk for CMV reactivation due to their immature immune system and therapy following transplantation. Reconstitution of CMV-specific T-cell immunity is associated with control and protection against CMV. The clinical utility of monitoring CMV-specific CMI to predict CMV viremia in pediatric HSCT patients using the Quantiferon-CMV (QIAGEN® ) test was investigated prospectively. Thirty-seven pediatric allogeneic HSCT recipients were enrolled from 3/2010-6/2012. CMV viremia was detected via weekly real-time PCR. The Quantiferon-CMV test was conducted pretransplant, early after transplantation, 30, 90, 180, 270, and 360 days post-transplantation. The incidence of CMV viremia was 51% (19/37) with half of the episodes within ≤30 days post-transplant. Fifteen patients showed CMV-specific immunity (average of 82 days). The cumulative incidence of CMV reactivation in patients who developed CMV-specific immunity was lower than those who did not (15% vs 53%; P = .023). The ROC statistical analysis showed that the AUC was 0.725 in predicting viremia, for Quantiferon-CMV test. In this cohort, the Quantiferon-CMV assay was a valuable method for identifying pediatric HSCT patients at high risk for CMV vire...Continue Reading

References

Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Per LjungmanCarlos Paya
Jun 3, 2004·Human Immunology·Holger Hebart, Hermann Einsele
Jan 18, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Per Ljungman
Sep 25, 2008·Bone Marrow Transplantation·P Ljungman
Dec 23, 2008·Immunity·Charles D Surh, Jonathan Sprent
Jan 13, 2009·Clinical Microbiology Reviews·Tania Crough, Rajiv Khanna
May 9, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·L Danziger-Isakov, P S Heeger
May 9, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D KumarA Humar
Mar 13, 2010·Transplantation·Camille N KottonUNKNOWN Transplantation Society International CMV Consensus Group
Nov 26, 2010·Transplantation Proceedings·A LochmanovaM Grundmann
Dec 8, 2010·British Journal of Haematology·Cécile RénardGérard Michel
Dec 22, 2010·Expert Review of Molecular Diagnostics·Stefano Giulieri, Oriol Manuel

❮ Previous
Next ❯

Citations

Feb 9, 2021·Frontiers in Immunology·Claudio AnnaloroFrancesco Onida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.